Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Tamsulosin on Postoperative Urinary Retention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II or greater pelvic organ prolapse in \> 1 vaginal compartment~* Plan for multicompartment native tissue vaginal repair (which would include any combination of uterosacral ligament suspension, sacrospinous ligament suspension, cystocele and/or rectocele repair, with or without hysterectomy and with or without concomitant mid-urethral sling) or vaginal closure with female pelvic medicine and reconstructive surgery (FPMRS) - trained surgeons at Wake Forest Baptist Health~* Participation in Enhanced-Recovery-After-Surgery protocol with plan for same-day hospital discharge~* Willing to remain compliant with Investigation Product (IP)~Exclusion Criteria:~* Intraoperative complication necessitating prolonged bladder drainage or placement of a vaginal pack x 24 hours (patients would exit study after randomization and will be excluded from the per-protocol analysis)~* Patients whose surgical plan would necessitate a voiding trial on postop day \>0~* Less than 21 years of age~* Unable to understand English~* Patients who are scheduled to undergo combined colorectal procedures such as rectopexy, sphincteroplasty~* Patient with known allergy to Tamsulosin or sulfa drugs~* Patients with upcoming cataract surgery~* Patient with orthostatic hypotension~* History of postvoid residual (PVR\>150) prior to surgery with prolapse reduction~* Patients with hypertension on alpha-blockers~* Single compartment prolapse repair (anterior or posterior repair only)~* Use of mesh for prolapse repair~* High tone pelvic floor dysfunction

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Tamsulosin (Type: EXPERIMENTAL): Patients in this arm will receive 10 days of 0.4 mg of oral tamsulosin once daily starting 5 days pre-operatively and continuing until all pills are completed.
- Placebo (Type: PLACEBO_COMPARATOR): Patients in this arm will receive 10 days of identical-appearing placebo once daily starting 5 days pre-operatively and continuing until all pills are completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).